Journal article · 2017 · Open access

The implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer

Jianbo Huang, Qingqing Luo, Yun Xiao, Hongyuan Li, Lingquan Kong, Guosheng Ren

Oncotarget, 8(64), 108249–108260 · Published 21 November 2017 · DOI 10.18632/oncotarget.22604

Open full textCite this paper

In brief

“The implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer” is a 2017 journal article by Jianbo Huang and 5 co-authors, published in Oncotarget. OpenAlex counts 32 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at Oncotarget.

Citations
32
Most cited in
2020 (7)
Field-weighted impact
1.10
References
22
Authors
6

Abstract

// Jianbo Huang 1, * , Qingqing Luo 1, * , Yun Xiao 2, * , Hongyuan Li 1 , Lingquan Kong 1 and Guosheng Ren 1 1 Department of Endocrine & Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China 2 Department of Oncology, Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China * These authors have contributed equally to this work Correspondence to: Guosheng Ren, email: rengs726@126.com Lingquan Kong, email: huihuikp@163.com Keywords: TNBC; RAS/RAF/ERK signaling pathway; GSEA; epirubicin; targeting therapy Received: July 20, 2017 Accepted: October 28, 2017 Published: November 21, 2017 ABSTRACT Background: Triple negative breast cancer (TNBC) is not sensitive to RAS/RAF/ERK signaling pathway (ERK pathway) targeting therapy, due to the absence of excessive activation of ERK pathway. However, the kinase cascades might be activated after chemotherapy in TNBC. Here we aimed to predict whether ERK pathway targeting therapy could be used as an adjuvant therapy in TNBC. Methods: Within online GEO datasets (GSE43816 and GSE54326), gene set enrichment analysis (GSEA) was performed to detect molecular changes in epirubicin treated TNBC samples and cells, ERK pathway components and regulation genes changes were included. Results: In epirubicin treated TNBC samples and cells, we found ERK pathway components (eg. MAPK13, MAP3K1, MAPK12, MAPK11 and MAPKAPK3) were obviously enriched, also, expression of ERK pathway positive regulation genes significantly increased ( P <0.05) and negative regulation genes decreased ( P <0.05) in epirubicin resistant cells. Moreover, phosphorylated ERK levels were significantly elevated in MDA-MB-231 cells after epirubicin treatment. Conclusion: ERK signaling pathway was more activated in epirubicin treated TNBC, possibly contributing to the epirubicin resistance in TNBC, it implicated that ERK pathway could be used as an novel candidate for targeting therapy in refractory and relapse TNBC.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Huang, J., Luo, Q., Xiao, Y., Li, H., Kong, L., & Ren, G. (2017). The implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer. Oncotarget, 8(64), 108249–108260. https://doi.org/10.18632/oncotarget.22604

MLA 9

Huang, Jianbo, et al. “The implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer.” Oncotarget, vol. 8, no. 64, 2017, pp. 108249–108260. https://doi.org/10.18632/oncotarget.22604.

Chicago

Huang, Jianbo, Qingqing Luo, Yun Xiao, Hongyuan Li, Lingquan Kong, and Guosheng Ren. 2017. “The implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer.” Oncotarget 8 (64): 108249–108260. https://doi.org/10.18632/oncotarget.22604.

Harvard

Huang, J. et al. (2017) ‘The implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer’, Oncotarget, 8(64), pp. 108249–108260. doi:10.18632/oncotarget.22604.

IEEE

J. Huang, Q. Luo, Y. Xiao, H. Li, L. Kong, and G. Ren, “The implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer,” Oncotarget, vol. 8, no. 64, pp. 108249–108260, 2017, doi: 10.18632/oncotarget.22604.

BibTeX

@article{huang2017implication,
  title     = {{The implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer}},
  author    = {Huang, Jianbo and Luo, Qingqing and Xiao, Yun and Li, Hongyuan and Kong, Lingquan and Ren, Guosheng},
  journal   = {Oncotarget},
  year      = {2017},
  volume    = {8},
  number    = {64},
  pages     = {108249--108260},
  doi       = {10.18632/oncotarget.22604},
  url       = {https://doi.org/10.18632/oncotarget.22604}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201722
201811
201933
202077
202155
202255
202311
202433
202522
202633

Its field-weighted citation impact is 1.10: it has been cited 1.10 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies

  • triple-negative breast cancer
  • epirubicin
  • epirubicin resistance
  • MAPK13
  • MAP3K1
  • MAPK12
  • MAPK11
  • MAPKAPK3

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Huang, J., Luo, Q., Xiao, Y., Li, H., Kong, L., & Ren, G. (2017). The implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer. Oncotarget, 8(64), 108249–108260. https://doi.org/10.18632/oncotarget.22604

How many times has this paper been cited?

32 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Oncotarget: sign in and open the full text from this page.

Who wrote this paper?

Jianbo Huang, Qingqing Luo, Yun Xiao, Hongyuan Li, Lingquan Kong, Guosheng Ren.

What is the DOI of this paper?

10.18632/oncotarget.22604, permanently at https://doi.org/10.18632/oncotarget.22604. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.